

NEWS RELEASE

UROPLASTY, INC. RAISES \$7.5 MILLION IN PRIVATE PLACEMENT OF COMMON STOCK AND WARRANTS

Thursday, April 21, 2005

MINNEAPOLIS, MN -- Uroplasty, Inc. (OTC Bulletin Board: UPST.OB), a medical device company that develops, manufactures and markets a family of minimally invasive products used to treat urinary and fecal voiding dysfunctions, announced today that it has closed a financing transaction principally with institutional investors generating gross proceeds to Uroplasty of \$7.5 million.

For the financing, Uroplasty has issued approximately 2.2 million shares of Common Stock at \$3.50 per share, as well as five-year warrants exercisable at \$4.75 per share to purchase an additional approximately 1.1 million shares of Common Stock. Uroplasty has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares.

Uroplasty plans to use the net proceeds from this transaction for general corporate purposes, including sales and marketing activities and product development. Craig Hallum Capital Group LLC acted as the exclusive placement agent for the transaction.

“As we plan and execute on new marketing strategies for our developing product lines, these funds will enhance our overall capabilities,” said Sam B. Humphries, President and Chief Executive Officer of Uroplasty, Inc. “This transaction also supplies us with the capital to meet our financial commitments and commence our work under the exclusive manufacturing and distribution agreement we entered into earlier this week with CystoMedix, Inc. for its percutaneous tibial nerve stimulation technology to treat overactive bladders,” he added.

The shares of Uroplasty’s Common Stock issued in conjunction with this transaction were issued pursuant to exemptions from the registration requirements of the Securities Act of 1933, as amended, and applicable state securities laws and are “restricted securities.” As such, the shares may not be offered or sold in the United States absent an exemption from, or registration under, the Securities Act and any applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of any offer to buy any such shares, nor shall there be any sale of Uroplasty’s Common Stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Uroplasty, Inc.

Uroplasty is a medical device company that develops, manufactures and markets a family of minimally invasive products used to treat urinary and fecal voiding dysfunctions. The company’s injectable implant products, CE-marked for sale outside the United States, offer physicians and their patients a minimally invasive treatment option for urinary incontinence, vesicoureteral reflux, fecal incontinence, vocal cord rehabilitation and dermal augmentation. Uroplasty is concluding a multi-center U.S. IDE clinical trial with its urethral bulking agent, *MACROPLASTIQUE*®, as a minimally invasive, office-based procedure for treating female stress urinary incontinence. The company also has exclusive manufacturing and marketing agreements with CL Medical of Lyon, France to manufacture and sell the I-Stop® mid-urethral sling tape in the United States for the treatment of female stress urinary incontinence, and with CystoMedix, Inc. of Andover, Minnesota for its nerve stimulation technology to treat overactive bladders.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. This press release contains forward-looking statements, including our internal projections of anticipated fiscal 2005 operating results, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words “aim,” “believe,” “expect,” “anticipate,” “intend,” “estimate” and other expressions which indicate future events and trends identify forward-looking statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing of our products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, particularly since our principal product contains silicone; our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of our current human clinical trial; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price.

FOR FURTHER INFORMATION: visit Uroplasty’s web page at www.uroplasty.com or contact Mr. Humphries.

UROPLASTY, INC.

Sam B. Humphries, President / CEO
2718 Summer Street N.E., Minneapolis, MN 55413-2820
Tel: 612-378-1180
Fax: 612-378-2027
E-mail: samh@uroplasty.com